SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ACADIA PHARMACEUTICALS INC
(NQNM:ACAD Last Sale: 46.59 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ACAD : $46.59)
$7,237,275 million Market Cap at Market Close, July 1, 2022
Employs 100.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
3911 Sorrento Valley Blvd Research Report Earnings Snapshot - Last 11/10/18
San Diego, CA 92121 Fact Sheet
Phone: (619) 558-2871 Financial Statements
Peer Comparison
Annual Reports

L.L. Iversen, Chmn., M.R. Brann, Pres., U. Hacksell, CEO, T.H. Aasen, CFO
Reported positive results Nov 27, 2012 - "an unprecedented advance for Parkinson’s patients who suffer from the psychosis frequently associated with this disease." Genomics-based drug discovery and development company that identifies target-specific small molecule drug candidates using its technology platform. IPO at $7 May 26, 2004. Raised $35 million, selling 5 million shares, 32% of the outstanding. Lead Manager: Banc of America Securities LLC. Released study results showing its experimental drug enhanced the power of a commonly used medication for schizophrenia, March 19, 2007.
Historical Charts    Technical Analysis
No Historical Data available for ACAD

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ACAD $46.59 $46.59 0 .0 $44.33 $46.6 1,138,989 $44.33 $46.6 155,339,667
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock #############

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex